Yana Konstantinovna Mangasarova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yana Konstantinovna Mangasarova has a total of 203 co-authors. Here are the top co-authors by number of shared publications:
- Eugene Eugeneevich Zvonkov
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
14 shared publications - Aminat U. Magomedova
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
12 shared publications - Alla Mikhailovna Kovrigina
National Medical Research Center for Hematology
11 shared publications - Yulia Alexandrovna Chabaeva
National Medical Research Center for Hematology, 125167 Moscow, Russia
8 shared publications - Ekaterina Sergeevna Nesterova
National Medical Research Center for Hematology, Ministry of Health of Russia
7 shared publications - Sergey Mikchailovich Kulikov
National Medical Research Center for Hematology, 125167 Moscow, Russia
7 shared publications
Latest Publications
- 26 August 2026
- Published by Media Sphere Publishing Group in Russian Bulletin of Obstetrician-Gynecologist
- Vol. 26 (4)
Lymphoproliferative diseases during pregnancy. Long-term outcomes for mother and child
Lymphoproliferative diseases are the third most common type of malignant neoplasms detected in pregnant patients. The high effectiveness of the therapy of such patients makes it relevant to study the long-term results of their treatment, as well as the health status of their children. Objective. To present the features of the course of pregnancy and its outcomes in patients with an identified lymphoproliferative disease during pregnancy, to evaluate the long-term effects of the treatment, as well as to analyze the physical development of children born to mothers with lymphoma, at birth and in the catamnesis. Materials and methods. From 2009 to 2025, 44 patients with a diagnosis of lymphoproliferative disease during pregnancy were treated at the Federal State Budgetary Institution “NMRC of Hematology” of the Ministry of Health of the Russian Federation. 28 (64%) pregnant women were diagnosed with non-Hodgkin’s lymphoma, 16 (36%) with Hodgkin’s lymphoma. Among 44 patients, 36 (82%) underwent chemotherapy during pregnancy, in 8 (18%), treatment was postponed until delivery. The median age of the patients at the time of the disease detection was 30 (range 20-39) years. In this retrospective single-center cohort study, we analyzed the development of 46 children born to 44 patients with detected lymphoma during gestation. Results. 43 (98%) of the 44 patients have been alive and are in remission of the disease with a median observation of 56 (range 2-186) months. 30 (68%) patients achieved complete remission after the first line of therapy. The remaining 14 (32%) patients required a second and subsequent line of treatment due to failure of the initial therapy. 6 (14%) cases of disease progression were registered during chemotherapy. Early relapses (1 year) — in 1 (2%) case. One patient died in the late postpartum period from septic complications after high-dose chemotherapy due to the progression of the disease. The median gestational age of newborns was 36 (range 26-40) weeks, 27 of 46 children (61%) were born prematurely. 22 newborns (49%) required follow-up in the intensive care unit. Congenital malformations of the cardiovascular system were detected in 2 babies (4%): 1 case (2%) of an open ductus arteriosus and 1 case (2%) of an interventricular septal defect. However, none of the identified pathological conditions required surgical intervention. At the time of the study, the median age of the children was 5.0 (range 0.3—15.3) years. The following LEN organs diseases were diagnosed later for 11 months among 46 children : adenoid hypertrophy — n=4 (9%), tonsillitis — n= 1 (2%), laryngitis — n=3 (7%), otitis media — n=3 (7%). One child (2%), whose mother did not receive chemotherapy during pregnancy, was diagnosed with cerebral palsy in the first year of life. Conclusion. Despite the diagnostic and therapeutic difficulties in verifying lymphoproliferative diseases during pregnancy, as well as the high frequency of premature birth, long-term catamnesis observations demonstrate favorable outcomes. The patients have long-term remissions, and the condition of their children is satisfactory in most cases.
- 26 August 2026
- Published by Media Sphere Publishing Group in Russian Bulletin of Obstetrician-Gynecologist
- Vol. 26 (4)
Lymphoproliferative diseases during pregnancy. Long-term outcomes for mother and child
Lymphoproliferative diseases are the third most common type of malignant neoplasms detected in pregnant patients. The high effectiveness of the therapy of such patients makes it relevant to study the long-term results of their treatment, as well as the health status of their children. Objective. To present the features of the course of pregnancy and its outcomes in patients with an identified lymphoproliferative disease during pregnancy, to evaluate the long-term effects of the treatment, as well as to analyze the physical development of children born to mothers with lymphoma, at birth and in the catamnesis. Materials and methods. From 2009 to 2025, 44 patients with a diagnosis of lymphoproliferative disease during pregnancy were treated at the Federal State Budgetary Institution “NMRC of Hematology” of the Ministry of Health of the Russian Federation. 28 (64%) pregnant women were diagnosed with non-Hodgkin’s lymphoma, 16 (36%) with Hodgkin’s lymphoma. Among 44 patients, 36 (82%) underwent chemotherapy during pregnancy, in 8 (18%), treatment was postponed until delivery. The median age of the patients at the time of the disease detection was 30 (range 20-39) years. In this retrospective single-center cohort study, we analyzed the development of 46 children born to 44 patients with detected lymphoma during gestation. Results. 43 (98%) of the 44 patients have been alive and are in remission of the disease with a median observation of 56 (range 2-186) months. 30 (68%) patients achieved complete remission after the first line of therapy. The remaining 14 (32%) patients required a second and subsequent line of treatment due to failure of the initial therapy. 6 (14%) cases of disease progression were registered during chemotherapy. Early relapses (1 year) — in 1 (2%) case. One patient died in the late postpartum period from septic complications after high-dose chemotherapy due to the progression of the disease. The median gestational age of newborns was 36 (range 26-40) weeks, 27 of 46 children (61%) were born prematurely. 22 newborns (49%) required follow-up in the intensive care unit. Congenital malformations of the cardiovascular system were detected in 2 babies (4%): 1 case (2%) of an open ductus arteriosus and 1 case (2%) of an interventricular septal defect. However, none of the identified pathological conditions required surgical intervention. At the time of the study, the median age of the children was 5.0 (range 0.3—15.3) years. The following LEN organs diseases were diagnosed later for 11 months among 46 children : adenoid hypertrophy — n=4 (9%), tonsillitis — n= 1 (2%), laryngitis — n=3 (7%), otitis media — n=3 (7%). One child (2%), whose mother did not receive chemotherapy during pregnancy, was diagnosed with cerebral palsy in the first year of life. Conclusion. Despite the diagnostic and therapeutic difficulties in verifying lymphoproliferative diseases during pregnancy, as well as the high frequency of premature birth, long-term catamnesis observations demonstrate favorable outcomes. The patients have long-term remissions, and the condition of their children is satisfactory in most cases.
- Open Access
- 17 July 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (2) , 227-237
Nivolumab and pregnancy in patients with classical Hodgkin lymphoma
Introduction . Classical Hodgkin lymphoma (cHL) is predominantly diagnosed in women of reproductive age. The expanding use of PD-1 inhibitors in the treatment of cHL increases the likelihood of pregnancy being detected during immunotherapy. However, only a limited number of such observations have been described in the literature, which complicates the choice of an optimal management strategy for these patients. Aim : to present two clinical case reports of patients with cHL: in the first, the beginning of pregnancy (4 weeks) occurred during nivolumab exposure; in the other patient, nivolumab was administered during the periconceptional period, 6 weeks before conception. Main Findings . In the first case, pregnancy was diagnosed at 6 weeks of gestation during maintenance therapy with nivolumab 40 mg every 2 weeks (cumulative dose 600 mg); the last dose was administered at 4 weeks of gestation, and treatment was discontinued after pregnancy was confirmed. Spontaneous delivery occurred at 38 weeks: a boy, birth weight 2910 g, length 49 cm, Apgar scores 8 and 9. In the second case, pregnancy was diagnosed at 3 weeks of gestation after completion of the Nivo-DHAP course with nivolumab at a dose of 240 mg. After pregnancy was confirmed, antitumor treatment was discontinued. Delivery at 38 weeks: cesarean section, a girl, birth weight 3000 g, length 52 cm, Apgar scores 8 and 9. The presented clinical case reports add to the limited clinical data on the course of pregnancy during the use of PD-1 inhibitors and highlight the need for multidisciplinary management and individualized decision-making, taking into account the potential risks to the mother and the fetus.
- 17 July 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (2) , 227-237
Open AccessNivolumab and pregnancy in patients with classical Hodgkin lymphoma
Introduction . Classical Hodgkin lymphoma (cHL) is predominantly diagnosed in women of reproductive age. The expanding use of PD-1 inhibitors in the treatment of cHL increases the likelihood of pregnancy being detected during immunotherapy. However, only a limited number of such observations have been described in the literature, which complicates the choice of an optimal management strategy for these patients. Aim : to present two clinical case reports of patients with cHL: in the first, the beginning of pregnancy (4 weeks) occurred during nivolumab exposure; in the other patient, nivolumab was administered during the periconceptional period, 6 weeks before conception. Main Findings . In the first case, pregnancy was diagnosed at 6 weeks of gestation during maintenance therapy with nivolumab 40 mg every 2 weeks (cumulative dose 600 mg); the last dose was administered at 4 weeks of gestation, and treatment was discontinued after pregnancy was confirmed. Spontaneous delivery occurred at 38 weeks: a boy, birth weight 2910 g, length 49 cm, Apgar scores 8 and 9. In the second case, pregnancy was diagnosed at 3 weeks of gestation after completion of the Nivo-DHAP course with nivolumab at a dose of 240 mg. After pregnancy was confirmed, antitumor treatment was discontinued. Delivery at 38 weeks: cesarean section, a girl, birth weight 3000 g, length 52 cm, Apgar scores 8 and 9. The presented clinical case reports add to the limited clinical data on the course of pregnancy during the use of PD-1 inhibitors and highlight the need for multidisciplinary management and individualized decision-making, taking into account the potential risks to the mother and the fetus.
- Open Access
- 1 July 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (3)
Pola-R-CHP Regimen as First-Line Therapy for Diffuse Large B-Cell Lymphoma: A Retrospective Study of Real-World Clinical Practice
BACKGROUND. For more than 20 years, the standard first-line therapy for diffuse large B-cell lymphoma (DLBCL) has been the R-CHOP regimen. However, about 30–40 % of patients experience relapsed/refractory disease. In the randomized POLARIX study, polatuzumab vedotin-based regimen (Pola-R-CHP) demonstrated a significant progression-free survival advantage over the standard R-CHOP. Yet, the evidence on the use of Pola-R-CHP in the real-world clinical practice in the Russian Federation is currently missing. AIM. To assess the efficacy and safety of the Pola-R-CHP regimen in patients with newly diagnosed DLBCL in a real-world setting in the Russian Federation. MATERIALS & METHODS. The multi-center retrospective study enrolled the data from 84 patients (48 men and 36 women) with immunomorphologically verified DLBCL diagnosis treated with polatuzumab vedotin-based first line therapy at 30 medical institutions of the Russian Federation in the period of 2022–2026. The median age of patients was 63 years (range 22–87 years). In 88 % of patients, DLBCL grade 3–4 was reported, 86 % belonged to a high-risk (IPI ≥ 3) group. The primary endpoint was complete response (CR) and overall response (OR) rate after 6 therapy cycles. Secondary endpoints included overall survival (OS), progression-free survival (PFS), metabolic response reported by PET/CT, and the analysis of safety profile. RESULTS. Full treatment was completed by 68 (81 %) out of 84 patients. After treatment, CR was 80.9 % and OR was 95.0 %. By PET/CT, complete metabolic response was achieved in 47/60 (78 %) patients. The median follow-up was 15.5 months. Neither median PFS nor median OS were achieved; the 2-year PFS was 82.5 % and the 2-year OS was 85.0 %. Most common adverse events (AEs) of any grade were neutropenia (67 %), leukopenia (55 %), anemia (35 %), and febrile neutropenia (14 %). AEs ≥ grade 3 were reported in 31 % of patients. CONCLUSION. In the real-world clinical practice in the Russian Federation, the Pola-R-CHP regimen showed high efficacy and favorable safety profile in the first-line therapy for DLBCL, also in the population of high-progression-risk patients. The results of the study are consistent with international data and prove the feasibility of risk-adapted treatment for DLBCL.
- 1 July 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (3)
Open AccessPola-R-CHP Regimen as First-Line Therapy for Diffuse Large B-Cell Lymphoma: A Retrospective Study of Real-World Clinical Practice
BACKGROUND. For more than 20 years, the standard first-line therapy for diffuse large B-cell lymphoma (DLBCL) has been the R-CHOP regimen. However, about 30–40 % of patients experience relapsed/refractory disease. In the randomized POLARIX study, polatuzumab vedotin-based regimen (Pola-R-CHP) demonstrated a significant progression-free survival advantage over the standard R-CHOP. Yet, the evidence on the use of Pola-R-CHP in the real-world clinical practice in the Russian Federation is currently missing. AIM. To assess the efficacy and safety of the Pola-R-CHP regimen in patients with newly diagnosed DLBCL in a real-world setting in the Russian Federation. MATERIALS & METHODS. The multi-center retrospective study enrolled the data from 84 patients (48 men and 36 women) with immunomorphologically verified DLBCL diagnosis treated with polatuzumab vedotin-based first line therapy at 30 medical institutions of the Russian Federation in the period of 2022–2026. The median age of patients was 63 years (range 22–87 years). In 88 % of patients, DLBCL grade 3–4 was reported, 86 % belonged to a high-risk (IPI ≥ 3) group. The primary endpoint was complete response (CR) and overall response (OR) rate after 6 therapy cycles. Secondary endpoints included overall survival (OS), progression-free survival (PFS), metabolic response reported by PET/CT, and the analysis of safety profile. RESULTS. Full treatment was completed by 68 (81 %) out of 84 patients. After treatment, CR was 80.9 % and OR was 95.0 %. By PET/CT, complete metabolic response was achieved in 47/60 (78 %) patients. The median follow-up was 15.5 months. Neither median PFS nor median OS were achieved; the 2-year PFS was 82.5 % and the 2-year OS was 85.0 %. Most common adverse events (AEs) of any grade were neutropenia (67 %), leukopenia (55 %), anemia (35 %), and febrile neutropenia (14 %). AEs ≥ grade 3 were reported in 31 % of patients. CONCLUSION. In the real-world clinical practice in the Russian Federation, the Pola-R-CHP regimen showed high efficacy and favorable safety profile in the first-line therapy for DLBCL, also in the population of high-progression-risk patients. The results of the study are consistent with international data and prove the feasibility of risk-adapted treatment for DLBCL.
- Open Access
- 1 April 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (2)
Efficacy and Safety of Glofitamab Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A United Russian Experience Based on the Compassionate Use Program
BACKGROUND. Clinical trials of glofitamab (Glofit) have demonstrated its high efficacy and tolerable toxicity profile in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients. However, the data on its use in a real-world setting remain sparse. AIM. To assess the efficacy and safety of Glofit in the combined cohort of R/R DLBCL patients in a real-world setting in the Russian Federation. MATERIALS & METHODS. This retrospective multi-center study enrolled 88 R/R DLBCL patients treated with Glofit under a compassionate use program from 2021 to 2024 in 22 Russian medical institutions. The median age of patients was 54 years (range 21–83 years), there were 42 (48 %) male patients. The main eligibility criteria were ≥ 3 prior therapy lines and exhaustion of available standard treatment methods. Glofit was administered as a monoregimen according to the schedule recommended in the package insert. RESULTS. With the follow-up median of 8.4 months (range 0.6–52 months), overall response was achieved in 46 (53 %) patients including 36 (42 %) patients with complete response (CR). The median overall survival (OS) was 13.1 months (95% confidence interval [95% CI] from 8.6 months to not reached), the 1-year OS was 55.7 % (95% CI 45.6–68.1 %). The median progression-free survival (PFS) was 4.2 months (95% CI 2.8–8.8 months), and the 1-year PFS was 33.5 % (95% CI 24.6–45.8 %). The median OS and PFS in patients with CR was not reached, whereas the 1-year PFS and OS were 73.7 % (95% CI 59.4–91.5 %) and 87.9 % (95% CI 77.4–99.9 %), respectively. Adverse events (AEs) were reported in 75 (85 %) patients, among them AEs of grade ≥ 3 in 35 (40 %) patients. Cytokine release syndrome was identified in 33 (38 %) patients, and “flare” syndrome was registered in 14 (16 %) patients. Infectious complications were observed in 45 (51 %) patients. Grade 5 AEs included only COVID-19 infection (n = 7; 8 %). Male gender, early relapse/refractoriness as well as 3-month administration of bendamustine prior to Glofit therapy were associated with the rate of achieving CR. PFS was lower in bendamustine recipients and also in cases with B-symptoms and massive tumor (bulky, > 7.5 cm). CONCLUSION. Glofit demonstrated high efficacy and tolerable toxicity profile in the treatment of R/R DLBCL patients. The results obtained in a real-world setting confirm the data from previously published clinical trials.
- 1 April 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (2)
Open AccessEfficacy and Safety of Glofitamab Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A United Russian Experience Based on the Compassionate Use Program
BACKGROUND. Clinical trials of glofitamab (Glofit) have demonstrated its high efficacy and tolerable toxicity profile in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients. However, the data on its use in a real-world setting remain sparse. AIM. To assess the efficacy and safety of Glofit in the combined cohort of R/R DLBCL patients in a real-world setting in the Russian Federation. MATERIALS & METHODS. This retrospective multi-center study enrolled 88 R/R DLBCL patients treated with Glofit under a compassionate use program from 2021 to 2024 in 22 Russian medical institutions. The median age of patients was 54 years (range 21–83 years), there were 42 (48 %) male patients. The main eligibility criteria were ≥ 3 prior therapy lines and exhaustion of available standard treatment methods. Glofit was administered as a monoregimen according to the schedule recommended in the package insert. RESULTS. With the follow-up median of 8.4 months (range 0.6–52 months), overall response was achieved in 46 (53 %) patients including 36 (42 %) patients with complete response (CR). The median overall survival (OS) was 13.1 months (95% confidence interval [95% CI] from 8.6 months to not reached), the 1-year OS was 55.7 % (95% CI 45.6–68.1 %). The median progression-free survival (PFS) was 4.2 months (95% CI 2.8–8.8 months), and the 1-year PFS was 33.5 % (95% CI 24.6–45.8 %). The median OS and PFS in patients with CR was not reached, whereas the 1-year PFS and OS were 73.7 % (95% CI 59.4–91.5 %) and 87.9 % (95% CI 77.4–99.9 %), respectively. Adverse events (AEs) were reported in 75 (85 %) patients, among them AEs of grade ≥ 3 in 35 (40 %) patients. Cytokine release syndrome was identified in 33 (38 %) patients, and “flare” syndrome was registered in 14 (16 %) patients. Infectious complications were observed in 45 (51 %) patients. Grade 5 AEs included only COVID-19 infection (n = 7; 8 %). Male gender, early relapse/refractoriness as well as 3-month administration of bendamustine prior to Glofit therapy were associated with the rate of achieving CR. PFS was lower in bendamustine recipients and also in cases with B-symptoms and massive tumor (bulky, > 7.5 cm). CONCLUSION. Glofit demonstrated high efficacy and tolerable toxicity profile in the treatment of R/R DLBCL patients. The results obtained in a real-world setting confirm the data from previously published clinical trials.
- Open Access
- 23 March 2026
- Published by Publishing House ABV Press in Oncohematology
- Vol. 21 (1)
Evolution of approaches to follicular lymphoma therapy at disease onset and first relapse. Twenty-five-year experience of the National Medical Research Center for Hematology
Background. In Russian clinical practice, there is no systematic information on patients with follicular lymphoma (FL) relapses after first-line therapy, and only isolated data are presented regarding the frequency of early and late relapses in the domestic population, first-line therapy regimens used in these patients, the dynamics of treatment response, timing of relapse, and second-line therapy regimens. A detailed analysis of a large cohort of patients with relapsed FL, including detailed clinical, laboratory, morphoimmunohistochemical, and molecular genetic characteristics, the treatments administered at onset and during relapse, as well as the identification of factors correlating with the risk of early progression, is of great scientific and practical interest. This is the focus of this study. Our results will be aimed at optimizing treatment and improving the prognosis of FL patients in Russia who have received second-line therapy. Aim. To describe changes in the therapeutic landscape of first-line FL therapy from 2001 to 2025 for patients receiving treatment at the National Medical Research Center for Hematology; to analyze the effectiveness of the therapeutic protocols used; to study cases of treatment resistance and identify significant factors influencing the prognosis of the disease; as well as to determine outcomes for patients with the first early relapse of nodal FL. Materials and methods. A retrospective and prospective study conducted from 2001 to 2025 at the National Medical Research Center of Hematology (Moscow) included 445 patients with newly diagnosed FL of cytological types 1–2 and 3A (World Health Organization, 2017). The median follow-up was 95 (1–251) months. All patients were treated according to the criteria of the Groupe d’Etude des Lymphomes Folliculaires. All patients included in the study were divided into two groups: those who received initial treatment between 2001 and 2022 (the historical control group; n = 374) and those who received initial treatment between 2022 and 2025 according to the new FL-2022 risk-based differentiated treatment protocol for patients with nodal FL (n = 71). Data for the two groups were analyzed separately. Results. With a median follow-up of 98 (1–251) months, the 2-year, 5-year, and 10-year overall survival of 374 patients from the historical control group (2001–2022) were 93, 90, and 85 %, respectively; 2-year, 5-year, and 10-year event-free survival were 82, 71, and 55 %, respectively. With high-dose chemotherapy, compared with standard regimens, the proportion of progressions / relapses was significantly lower (26 % versus 40 %; p = 0.01), but if events occurred, they were predominantly early (72 % versus 58 %; p = 0.2). According to the results of multivariate analysis, independent prognostic risk factors for disease progression within 24 months after the start of therapy (POD24) were identified: absence of BCL2 gene rearrangement (odds ratio 3.52 (1.89–6.55); p 0.0001) and 3A cytological type (odds ratio 3.8 (1.61–0.16); p = 0.0033). During second-line therapy in the first early relapse / progression after R-B (rituximab + bendamustine), R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone) and autologous hematopoietic stem cell transplantation, complete remission was achieved in only 38 % of patients, and after R-DHAP it was not achieved in any case. With therapy according to the FL-2022 protocol (2022–2025), with a median follow-up of 23 months, 2-year overall survival was 100 %, 2-year event-free survival was 97 %. Second-line therapy was required in only 6 % of patients. Conclusion. The development of early relapse / progression has a critical impact on the survival prognosis of FL patients. The use of a differentiated treatment protocol for patients with nodal FL (FL-2022), based on clinical, morphological, immunohistochemical, and genetic prognostic factors, has significantly improved treatment outcomes and reduced the risk of POD24. When FL first relapses, there is no uniform treatment standard, and the regimens used vary greatly. Treatment outcomes in the first relapse remain modest, especially for the high-risk POD24 group, necessitating a change in the treatment paradigm for this patient group.
- 23 March 2026
- Published by Publishing House ABV Press in Oncohematology
- Vol. 21 (1)
Open AccessEvolution of approaches to follicular lymphoma therapy at disease onset and first relapse. Twenty-five-year experience of the National Medical Research Center for Hematology
Background. In Russian clinical practice, there is no systematic information on patients with follicular lymphoma (FL) relapses after first-line therapy, and only isolated data are presented regarding the frequency of early and late relapses in the domestic population, first-line therapy regimens used in these patients, the dynamics of treatment response, timing of relapse, and second-line therapy regimens. A detailed analysis of a large cohort of patients with relapsed FL, including detailed clinical, laboratory, morphoimmunohistochemical, and molecular genetic characteristics, the treatments administered at onset and during relapse, as well as the identification of factors correlating with the risk of early progression, is of great scientific and practical interest. This is the focus of this study. Our results will be aimed at optimizing treatment and improving the prognosis of FL patients in Russia who have received second-line therapy. Aim. To describe changes in the therapeutic landscape of first-line FL therapy from 2001 to 2025 for patients receiving treatment at the National Medical Research Center for Hematology; to analyze the effectiveness of the therapeutic protocols used; to study cases of treatment resistance and identify significant factors influencing the prognosis of the disease; as well as to determine outcomes for patients with the first early relapse of nodal FL. Materials and methods. A retrospective and prospective study conducted from 2001 to 2025 at the National Medical Research Center of Hematology (Moscow) included 445 patients with newly diagnosed FL of cytological types 1–2 and 3A (World Health Organization, 2017). The median follow-up was 95 (1–251) months. All patients were treated according to the criteria of the Groupe d’Etude des Lymphomes Folliculaires. All patients included in the study were divided into two groups: those who received initial treatment between 2001 and 2022 (the historical control group; n = 374) and those who received initial treatment between 2022 and 2025 according to the new FL-2022 risk-based differentiated treatment protocol for patients with nodal FL (n = 71). Data for the two groups were analyzed separately. Results. With a median follow-up of 98 (1–251) months, the 2-year, 5-year, and 10-year overall survival of 374 patients from the historical control group (2001–2022) were 93, 90, and 85 %, respectively; 2-year, 5-year, and 10-year event-free survival were 82, 71, and 55 %, respectively. With high-dose chemotherapy, compared with standard regimens, the proportion of progressions / relapses was significantly lower (26 % versus 40 %; p = 0.01), but if events occurred, they were predominantly early (72 % versus 58 %; p = 0.2). According to the results of multivariate analysis, independent prognostic risk factors for disease progression within 24 months after the start of therapy (POD24) were identified: absence of BCL2 gene rearrangement (odds ratio 3.52 (1.89–6.55); p 0.0001) and 3A cytological type (odds ratio 3.8 (1.61–0.16); p = 0.0033). During second-line therapy in the first early relapse / progression after R-B (rituximab + bendamustine), R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone) and autologous hematopoietic stem cell transplantation, complete remission was achieved in only 38 % of patients, and after R-DHAP it was not achieved in any case. With therapy according to the FL-2022 protocol (2022–2025), with a median follow-up of 23 months, 2-year overall survival was 100 %, 2-year event-free survival was 97 %. Second-line therapy was required in only 6 % of patients. Conclusion. The development of early relapse / progression has a critical impact on the survival prognosis of FL patients. The use of a differentiated treatment protocol for patients with nodal FL (FL-2022), based on clinical, morphological, immunohistochemical, and genetic prognostic factors, has significantly improved treatment outcomes and reduced the risk of POD24. When FL first relapses, there is no uniform treatment standard, and the regimens used vary greatly. Treatment outcomes in the first relapse remain modest, especially for the high-risk POD24 group, necessitating a change in the treatment paradigm for this patient group.
- Open Access
- 10 December 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (4) , 63-75
Bridging therapy prior to CAR-T in non-Hodgkin lymphomas: rationale and impact on outcomes
In patients with aggressive, rapidly progressive B-cell non-Hodgkin lymphomas (NHL), the waiting window between leukapheresis and infusion of chimeric antigen receptor (CAR) T-cells carries a risk of clinical deterioration, disease progression, and dropout from therapy. Bridging therapy (BT) aims to maintain disease control until infusion and to reduce tumor burden – factors that are both associated with improved outcomes after CAR T-cell therapy. Despite the wide range of approaches used (radiation therapy, polatuzumab-based regimens, bispecific antibodies, Bruton’s tyrosine kinase inhibitors, and glucocorticoids), BT is prescribed at the discretion of the attending physician. Aim – to systematize available data on the efficacy and safety of different BT options and to assess their impact on outcomes of CAR T-cell therapy in non-Hodgkin lymphomas. Bridging therapy is defined as any antitumor therapy administered after leukapheresis and before lymphodepletion with the goal of stabilizing disease or reducing tumor burden prior to CAR T-cell infusion.
- 10 December 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (4) , 63-75
Open AccessBridging therapy prior to CAR-T in non-Hodgkin lymphomas: rationale and impact on outcomes
In patients with aggressive, rapidly progressive B-cell non-Hodgkin lymphomas (NHL), the waiting window between leukapheresis and infusion of chimeric antigen receptor (CAR) T-cells carries a risk of clinical deterioration, disease progression, and dropout from therapy. Bridging therapy (BT) aims to maintain disease control until infusion and to reduce tumor burden – factors that are both associated with improved outcomes after CAR T-cell therapy. Despite the wide range of approaches used (radiation therapy, polatuzumab-based regimens, bispecific antibodies, Bruton’s tyrosine kinase inhibitors, and glucocorticoids), BT is prescribed at the discretion of the attending physician. Aim – to systematize available data on the efficacy and safety of different BT options and to assess their impact on outcomes of CAR T-cell therapy in non-Hodgkin lymphomas. Bridging therapy is defined as any antitumor therapy administered after leukapheresis and before lymphodepletion with the goal of stabilizing disease or reducing tumor burden prior to CAR T-cell infusion.
- Open Access
- 5 October 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (3) , 296-310
Clinical and morphological analysis and evaluation of treatment results of patients with primary testicular diffuse large B-cell lymphoma
Introduction. Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) is characterized by an aggressive course and a high relapse rate when using standard therapy protocols. A feature of PT-DLBCL is its high tropism for central nervous system damage. Aim: to compare the treatment outcomes of patients with PT-DLBCL treated with known protocols and according to the “PTL2022” protocol. Materials and Methods. From 2006 to 2025, 54 patients with PT-DLBCL were included in the analysis: 12 patients in the prospective group and 42 patients in the retrospective control group. Results. CNS involvement at the onset of PT-DLBCL in the prospective group was present in 60 % of patients, in the retrospective group the frequency of CNS involvement is unknown. In the entire group of all 54 patients with PT-DLBCL, event-free survival (EFS) and overall survival (OS) were 20 % and 29 %, respectively. In the retrospective group, EFS was 17%, in the prospective group 90 %, OS — 28 % and 90 %, respectively. Conclusion. The “PTL-2022” protocol is reproducible, effective and safe in different age groups of patients. An improvement of treatment outcomes with the “PTL-2022” protocol was established in the high-risk group.
- 5 October 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (3) , 296-310
Open AccessClinical and morphological analysis and evaluation of treatment results of patients with primary testicular diffuse large B-cell lymphoma
Introduction. Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) is characterized by an aggressive course and a high relapse rate when using standard therapy protocols. A feature of PT-DLBCL is its high tropism for central nervous system damage. Aim: to compare the treatment outcomes of patients with PT-DLBCL treated with known protocols and according to the “PTL2022” protocol. Materials and Methods. From 2006 to 2025, 54 patients with PT-DLBCL were included in the analysis: 12 patients in the prospective group and 42 patients in the retrospective control group. Results. CNS involvement at the onset of PT-DLBCL in the prospective group was present in 60 % of patients, in the retrospective group the frequency of CNS involvement is unknown. In the entire group of all 54 patients with PT-DLBCL, event-free survival (EFS) and overall survival (OS) were 20 % and 29 %, respectively. In the retrospective group, EFS was 17%, in the prospective group 90 %, OS — 28 % and 90 %, respectively. Conclusion. The “PTL-2022” protocol is reproducible, effective and safe in different age groups of patients. An improvement of treatment outcomes with the “PTL-2022” protocol was established in the high-risk group.
- Open Access
- 20 May 2025
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 6, 1002318
Prognostic impact of biomarkers in PMBCL: rationale for early integration of immune checkpoint inhibitors
Aim: This research aims to guide future strategies for personalized treatment of primary mediastinal large B-cell lymphoma (PMBCL), particularly to identify high-risk patients who may benefit from incorporating immune checkpoint inhibitors (ICIs) in the first-line setting. Methods: A retrospective, single-center study included 254 newly diagnosed PMBCL patients treated with rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (R-DA-EPOCH), rituximab, modified protocol NHL-BFM-90 (RmNHL-BFM-90), or R-DA-EPOCH combined with nivolumab. Clinical parameters, immunohistochemical markers [programmed death ligand-1 (PD-L1), programmed death-1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), human leucocyte antigen (HLA)-DR, Ki-67, multiple myeloma oncogene 1 (MUM1)], molecular markers (mutations in tumor protein p53 (TP53), CD58, beta-2-microglobulin (B2M), and exportin 1 (XPO1) genes; short tandem repeats at 6p21.3 [major histocompatibility complex (MHC) class I/II], 9p24.1 (PD-L1/PD-L2), 16p13.13 [class II, MHC, transactivator gene (CIITA)]), and cytogenetic profiles [myelocytomatosis oncogene (MYC)/8q24, B-cell lymphoma 2 (BCL2)/18q21, BCL6/3q27, del17p13, and karyotype abnormalities] were analyzed. Results: The addition of nivolumab to R-DA-EPOCH as a first-line regimen significantly improved event-free survival (EFS; P = 0.018). This study identified that adverse prognostic factors for PMBCL include allelic imbalance at specific loci 6p21.3 (MHC class I/II), 9p24.1 (PD-L1/PD-L2), and 16p13.13 (CIITA). Incorporating nivolumab into the R-DA-EPOCH regimen as a first-line therapy has shown potential in reducing adverse prognostic factors. Conclusions: These findings suggest that high-risk patients may benefit significantly from the early incorporation of ICIs into their treatment plans.
- 20 May 2025
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 6, 1002318
Open AccessPrognostic impact of biomarkers in PMBCL: rationale for early integration of immune checkpoint inhibitors
Aim: This research aims to guide future strategies for personalized treatment of primary mediastinal large B-cell lymphoma (PMBCL), particularly to identify high-risk patients who may benefit from incorporating immune checkpoint inhibitors (ICIs) in the first-line setting. Methods: A retrospective, single-center study included 254 newly diagnosed PMBCL patients treated with rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (R-DA-EPOCH), rituximab, modified protocol NHL-BFM-90 (RmNHL-BFM-90), or R-DA-EPOCH combined with nivolumab. Clinical parameters, immunohistochemical markers [programmed death ligand-1 (PD-L1), programmed death-1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), human leucocyte antigen (HLA)-DR, Ki-67, multiple myeloma oncogene 1 (MUM1)], molecular markers (mutations in tumor protein p53 (TP53), CD58, beta-2-microglobulin (B2M), and exportin 1 (XPO1) genes; short tandem repeats at 6p21.3 [major histocompatibility complex (MHC) class I/II], 9p24.1 (PD-L1/PD-L2), 16p13.13 [class II, MHC, transactivator gene (CIITA)]), and cytogenetic profiles [myelocytomatosis oncogene (MYC)/8q24, B-cell lymphoma 2 (BCL2)/18q21, BCL6/3q27, del17p13, and karyotype abnormalities] were analyzed. Results: The addition of nivolumab to R-DA-EPOCH as a first-line regimen significantly improved event-free survival (EFS; P = 0.018). This study identified that adverse prognostic factors for PMBCL include allelic imbalance at specific loci 6p21.3 (MHC class I/II), 9p24.1 (PD-L1/PD-L2), and 16p13.13 (CIITA). Incorporating nivolumab into the R-DA-EPOCH regimen as a first-line therapy has shown potential in reducing adverse prognostic factors. Conclusions: These findings suggest that high-risk patients may benefit significantly from the early incorporation of ICIs into their treatment plans.
- Open Access
- 4 May 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (1) , 4-7
2024 events that may change the clinical practice for aggressive B-cell lymphomas in the future
The data presented at the 2024 international conferences on the diagnosis and treatment of aggressive B-cell lymphomas were reviewed; 13 striking and important events that could change clinical practice in the future were identified. The presented studies evaluated the efficacy of new therapies for diffuse large B-cell lymphoma in both first-line therapy and relapse settings. The absolute top pick is bispecific antibodies; their efficacy and safety are evaluated in various combinations to develop an optimal strategy for their use at different stages of therapy. There are also two most striking studies on CAR T-cell therapy.
- 4 May 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (1) , 4-7
Open Access2024 events that may change the clinical practice for aggressive B-cell lymphomas in the future
The data presented at the 2024 international conferences on the diagnosis and treatment of aggressive B-cell lymphomas were reviewed; 13 striking and important events that could change clinical practice in the future were identified. The presented studies evaluated the efficacy of new therapies for diffuse large B-cell lymphoma in both first-line therapy and relapse settings. The absolute top pick is bispecific antibodies; their efficacy and safety are evaluated in various combinations to develop an optimal strategy for their use at different stages of therapy. There are also two most striking studies on CAR T-cell therapy.
- Open Access
- 27 December 2024
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 69 (4) , 392-409
Multicenter randomized controlled (comparative) open prospective study to evaluate the efficacy of the R-DA-EPOCH-21 and R-mNHL-BFM-90 with and without autologous hematopoietic stem cell transplantation programs in untreated patients with de novo diffuse B-cell large cell lymphoma with signs of poor prognosis (final results)
Introduction. The R-NHL-BFM-90 protocol has been successfully used for the treatment of Burkitt’s lymphoma and diffuse large B-cell lymphoma (DLBCL) in children and adolescents, as well as adult T-cell lymphomas. The protocol was modified for the treatment of adult patients with de novo nodal DLBCL.Aim: to evaluate the efficacy and toxicity of the R-mNHL-BFM-90 and R-DA-EPOCH-21 protocols in adult patients with de novo nodal DLBCL with 2 or more signs of poor prognosis, as well as to determine the role of auto-HSCT in the consolidation of remission.Materials and methods. From 2015 to 2021, 164 patients were evaluated for randomization. The study included 140 patients from 13 Russian medical centers. 89 (76 %) patients with de novo nodal DLBCL: R-DAEPOCH-21 20 (22.5 %) patients; R-DAEPOCH-21 + auto-HSCT 21 (23.5 %) patients; R-mNHL-BFM-90 20 (22.5 %) patients; R-mNHL-BFM-90 performed + auto-HSCT 28 (31.5 %) patients. In the high-intermediate and high-risk group, there were 12 (29.3 %) and 29 (70.7 %) patients on the R-DA-EPOCH-21 + auto-HSCT protocol and 15 (31.2 %) and 32 (66.7 %) on the R-mNHL-BFM-90 protocol + auto-HSCT, respectively.Results. The R-mNHL-BFM-90 protocol proved to be more effective. Complete remission in the high-risk group was achieved in 30 (93.7 %) patients versus 18 (62.0 %), there was no progression versus 3 (10.3 %) patients treated according to R-DA-EPOCH-21 (p = 0.0167). The five-year overall and event-free survival in the high-risk group was 97 % vs. 75 % (p = 0.01) and 97 % vs. 72 % (p = 0.0026), respectively. In the intermediate risk group, the results of therapy did not differ. The toxicity of the R-mNHL-BFM-90 protocol exceeded the toxicity of R-DA-EPOCH-21 only in neutropenic fever (p = 0.04) and grade 3–4 thrombocytopenia (p = 0.0009).Conclusion. The R-mNHL-BFM-90 protocol is effective for the treatment of patients with nodal de novo DLBCL diffuse large B-cell lymphoma of high-risk adults; its toxicity is acceptable. However, on the R-DA-EPOCH-21 therapy, the results of therapy are unsatisfactory. The R-DA-EPOCH-21 protocol with auto-HSCT was more effective than without auto-HSCT, however, due to the small number of patients, the results were unpresentative. The results of therapy according R-mNHL-BFM-90 protocol with auto-HSCT and without auto-HSCT were not differ.
- 27 December 2024
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 69 (4) , 392-409
Open AccessMulticenter randomized controlled (comparative) open prospective study to evaluate the efficacy of the R-DA-EPOCH-21 and R-mNHL-BFM-90 with and without autologous hematopoietic stem cell transplantation programs in untreated patients with de novo diffuse B-cell large cell lymphoma with signs of poor prognosis (final results)
Introduction. The R-NHL-BFM-90 protocol has been successfully used for the treatment of Burkitt’s lymphoma and diffuse large B-cell lymphoma (DLBCL) in children and adolescents, as well as adult T-cell lymphomas. The protocol was modified for the treatment of adult patients with de novo nodal DLBCL.Aim: to evaluate the efficacy and toxicity of the R-mNHL-BFM-90 and R-DA-EPOCH-21 protocols in adult patients with de novo nodal DLBCL with 2 or more signs of poor prognosis, as well as to determine the role of auto-HSCT in the consolidation of remission.Materials and methods. From 2015 to 2021, 164 patients were evaluated for randomization. The study included 140 patients from 13 Russian medical centers. 89 (76 %) patients with de novo nodal DLBCL: R-DAEPOCH-21 20 (22.5 %) patients; R-DAEPOCH-21 + auto-HSCT 21 (23.5 %) patients; R-mNHL-BFM-90 20 (22.5 %) patients; R-mNHL-BFM-90 performed + auto-HSCT 28 (31.5 %) patients. In the high-intermediate and high-risk group, there were 12 (29.3 %) and 29 (70.7 %) patients on the R-DA-EPOCH-21 + auto-HSCT protocol and 15 (31.2 %) and 32 (66.7 %) on the R-mNHL-BFM-90 protocol + auto-HSCT, respectively.Results. The R-mNHL-BFM-90 protocol proved to be more effective. Complete remission in the high-risk group was achieved in 30 (93.7 %) patients versus 18 (62.0 %), there was no progression versus 3 (10.3 %) patients treated according to R-DA-EPOCH-21 (p = 0.0167). The five-year overall and event-free survival in the high-risk group was 97 % vs. 75 % (p = 0.01) and 97 % vs. 72 % (p = 0.0026), respectively. In the intermediate risk group, the results of therapy did not differ. The toxicity of the R-mNHL-BFM-90 protocol exceeded the toxicity of R-DA-EPOCH-21 only in neutropenic fever (p = 0.04) and grade 3–4 thrombocytopenia (p = 0.0009).Conclusion. The R-mNHL-BFM-90 protocol is effective for the treatment of patients with nodal de novo DLBCL diffuse large B-cell lymphoma of high-risk adults; its toxicity is acceptable. However, on the R-DA-EPOCH-21 therapy, the results of therapy are unsatisfactory. The R-DA-EPOCH-21 protocol with auto-HSCT was more effective than without auto-HSCT, however, due to the small number of patients, the results were unpresentative. The results of therapy according R-mNHL-BFM-90 protocol with auto-HSCT and without auto-HSCT were not differ.